MALT (psychedelic drug)
MALT (N-methyl-N-allyltryptamine or N,N-methylallyltryptamine) is a lesser-known drug from the tryptamine family. It is a novel compound with very little history of human use. It is closely related to methylpropyltryptamine (MPT), as well as N-methyltryptamine. It has been sold online as a designer drug. Very little information on the pharmacology or toxicity of MALT is available.
![]() | |
| Names | |
|---|---|
| Systematic IUPAC name
N-[2-(1H-Indol-3-yl)ethyl]-N-methylprop-2-en-1-amine | |
| Other names
N,N-Methylallyltyptamine | |
| Identifiers | |
3D model (JSmol) |
|
PubChem CID |
|
| UNII | |
| |
| |
| Pharmacology | |
| Oral, insufflated, rectal, smoked, IM, IV | |
| Legal status |
|
| Properties | |
| C14H18N2 | |
| Molar mass | 214.312 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |

Legality
MALT is not explicitly scheduled in any countries; however, it could be considered a psychoactive substance under the UK Psychoactive Substances Act, which requires the prosecutor to prove that the substance is psychoactive in order for a person to be charged with an offense.[1]
It could also be considered a structural analog of a scheduled substance under the US Federal Analogue Act due to its similarity to scheduled tryptamines.
See also
- 5-Methoxy-N,N-Methylallyltryptamine (5-MeO-MALT)
- N,N-Diallyltryptamine (DALT)
- Methylpropyltryptamine (MPT)
Further reading
- Chadeayne, Andrew R.; Pham, Duyen N. K.; Golen, James A.; Manke, David R. (2020). "DMT analogues: N-ethyl-N-propyltryptamine and N-allyl-N-methytryptamine as their hydrofumarate salts". Acta Crystallographica Section E. 76 (8): 1201–1205. doi:10.1107/S2056989020008683. PMC 7405555. PMID 32843999.
- Brandt, S. D.; Freeman, S.; Fleet, I. A.; McGagh, P.; Alder, J. F. (2004). "Analytical chemistry of synthetic routes to psychoactive tryptamines". The Analyst. 129 (11): 1047–1057. doi:10.1039/b407239c. PMID 15508033.
References
- "Psychoactive Substances Act Guidance" (PDF). Retrieved 2021-09-23.
{{cite web}}: CS1 maint: url-status (link)
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
|
